Literature DB >> 23689239

Current status of implementation of self-administration training in various regions of Europe, Canada and the USA in the management of hereditary angioedema.

T Caballero1, A Sala-Cunill, M Cancian, T J Craig, S Neri, P K Keith, I Boccon-Gibod, C Bethune, K Bork.   

Abstract

Results from a 16-question survey about self-administration of hereditary angioedema (HAE) therapy, administered in Europe, Canada and the USA, were used to guide discussion at an international HAE expert meeting. The aim was to capture information about current practice in self-administered HAE therapy in these countries, including self-administration training, the key benefits of switching to self-administration, the barriers to self-administration and trends in self-administration. Overall, switching to self-administration therapy is looked upon favourably from both patient and clinician perspectives by virtue of the potential improvement in quality of life arising from optimisation of therapy and early intervention. The recent changes to product licences allowing self-administration provide additional options for the management of HAE.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689239     DOI: 10.1159/000351233

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  10 in total

Review 1.  Hereditary angioedema: what the gastroenterologist needs to know.

Authors:  M Aamir Ali; Marie L Borum
Journal:  Clin Exp Gastroenterol       Date:  2014-11-20

2.  Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema.

Authors:  Atsushi Satomura; Takayuki Fujita; Tomohiro Nakayama
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

3.  Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.

Authors:  Hilary J Longhurst; John Dempster; Lorena Lorenzo; Matthew Buckland; Sofia Grigoriadou; Christine Symons; Claire Bethune; Vincent Fabien; Catherine Bangs; Tomaz Garcez
Journal:  Allergy Asthma Clin Immunol       Date:  2018-08-06       Impact factor: 3.406

4.  Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema.

Authors:  Rosanna Spanò; Nadia Di Paola; Maria Bova; Alessandro Barbarino
Journal:  BMC Health Serv Res       Date:  2018-07-20       Impact factor: 2.655

5.  Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

Authors:  Elyse Murphy; Christine Donahue; Laurel Omert; Stephanie Persons; Thomas J Tyma; Joseph Chiao; William Lumry
Journal:  Nurs Open       Date:  2018-08-28

Review 6.  Management of hereditary angioedema in pregnant women: a review.

Authors:  Teresa Caballero; Julio Canabal; Daniela Rivero-Paparoni; Rosario Cabañas
Journal:  Int J Womens Health       Date:  2014-09-09

7.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Authors:  Veronica Squeglia; Alessandro Barbarino; Maria Bova; Carmela Gravante; Angelica Petraroli; Giuseppe Spadaro; Massimo Triggiani; Arturo Genovese; Gianni Marone
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

8.  Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey.

Authors:  Aleena Banerji; Murat Baş; Jonathan A Bernstein; Isabelle Boccon-Gibod; Maria Bova; John Dempster; Anete Sevciovic Grumach; Markus Magerl; Kimberly Poarch; Manuel Branco Ferreira
Journal:  Allergy Rhinol (Providence)       Date:  2016-09-22

9.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.

Authors:  H Farkas; I Martinez-Saguer; K Bork; T Bowen; T Craig; M Frank; A E Germenis; A S Grumach; A Luczay; L Varga; A Zanichelli
Journal:  Allergy       Date:  2016-09-08       Impact factor: 13.146

10.  Practicalities of a reduced volume formulation of a C1-INH concentrate for the treatment of hereditary angioedema: real-life experience.

Authors:  John Dempster
Journal:  Allergy Asthma Clin Immunol       Date:  2018-10-25       Impact factor: 3.406

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.